MOBERG PHARMA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.7 SEK | -9.52% |
|
-21.59% | +62.50% |
| May. 14 | Moberg Pharma AB Elects Jonas Ekblom as Board Member | CI |
| May. 07 | Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presentation Operator MessageOperator (Operator)Hello, and welcome to Moberg Pharma Q3 report ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q2 2024 Earnings Release
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +62.50% | 71.33M | |
| +32.03% | 694B | |
| +29.39% | 593B | |
| -1.47% | 371B | |
| +19.96% | 331B | |
| +7.25% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.48% | 169B |
- Stock Market
- Equities
- MOB Stock
- News Moberg Pharma AB
- Transcript : Moberg Pharma AB, Nine Months 2021 Earnings Call, Nov 09, 2021
